AUCKLAND Wednesday, 24 September 2025 - Roche Products (New Zealand) Ltd today welcomed Pharmac’s decision to consult on proposed funding of four treatments that could transform care for thousands of ...

If your vision is blurry or fuzzy, or if you notice that straight lines appear curved or wavy, they could be symptoms of ...

A study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 found that individuals with ...

There is no cure for dry AMD, but if vision loss progresses, your doctor may suggest devices for low vision, such as telescopes, magnifiers, or phones with large print. An augmented reality visor has ...

Paris, France, Thursday, 18 September 2025) New research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

New research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that people with psoriasis face a significantly increased risk of developing ...

Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its ...

Wet AMD happens when new blood vessels grow underneath the retina. Fluid can escape from these new blood vessels and builds up within the retina, causing damage and a change in vision. "If you ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo ® (faricimab-svoa), presented at the 25th Euretina ...